I
Indra Neil Guha
Researcher at Nottingham University Hospitals NHS Trust
Publications - 119
Citations - 4750
Indra Neil Guha is an academic researcher from Nottingham University Hospitals NHS Trust. The author has contributed to research in topics: Cirrhosis & Liver disease. The author has an hindex of 28, co-authored 105 publications receiving 3302 citations. Previous affiliations of Indra Neil Guha include Southampton General Hospital & University of Nottingham.
Papers
More filters
Journal ArticleDOI
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.
Indra Neil Guha,Julie Parkes,Paul Roderick,Dipanker Chattopadhyay,Richard Cross,Scott Harris,Philip Kaye,Alastair D. Burt,Steve D. Ryder,Guruprasad P. Aithal,Christopher P. Day,William Rosenberg +11 more
TL;DR: The ELF panel has good diagnostic accuracy in an independent validation cohort of patients with NAFLD and the addition of established simple markers augments the diagnostic performance across different stages of fibrosis, which will potentially allow superior stratification of patients for emerging therapeutic strategies.
Journal ArticleDOI
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Peter J Eddowes,Magali Sasso,Michael Allison,Emmanouil Tsochatzis,Quentin M. Anstee,David Sheridan,Indra Neil Guha,Jeremy F. L. Cobbold,Jonathan J Deeks,Valérie Paradis,Pierre Bedossa,Philip N. Newsome,Philip N. Newsome +12 more
TL;DR: In a prospective analysis of patients with NAFLD, FibroScan vibration-controlled transient elastography controlled attenuation parameter (CAP) and liver stiffness measurement (LSMs) found to be effective in assessing liver steatosis and fibrosis, respectively, with AUROC values ranging from 0.70 to 0.89.
Journal ArticleDOI
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Philip N. Newsome,Philip N. Newsome,Magali Sasso,Jonathan J Deeks,Jonathan J Deeks,Angelo H. Paredes,Jérôme Boursier,Wah-Kheong Chan,Yusuf Yilmaz,Sébastien Czernichow,Ming-Hua Zheng,Ming-Hua Zheng,Vincent Wai-Sun Wong,Michael Allison,Emmanuel Tsochatzis,Quentin M. Anstee,David Sheridan,Peter J Eddowes,Indra Neil Guha,Jeremy F. L. Cobbold,Valérie Paradis,Pierre Bedossa,Véronique Miette,Céline Fournier-Poizat,Laurent Sandrin,Stephen A. Harrison +25 more
TL;DR: The FAST score provides an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments when they become available, and thereby reduce unnecessary liver biopsy in patients unlikely to have significant disease.
Journal ArticleDOI
Performance of serum marker panels for liver fibrosis in chronic hepatitis C
TL;DR: Serum markers can rule-in or rule-out fibrosis in up to 35% of patients, but cannot differentiate stages of fibrosis reliably.
Journal ArticleDOI
Prediction, prevention and management of postresection liver failure
TL;DR: The aim of this review article is to present strategies to predict, prevent and manage PLF.